GC Therapeutics harnesses an induced pluripotent stem cell (iPSC) cellular programming platform to improve patient access across various therapeutic areas, focusing on gastrointestinal, neurological, and immunological diseases.

GC Therapeutics

Squarespace Hosted

Scientific Co-Founder and Head of Discovery Platforms

Cory Smith

CEO & Co-Founder

Parastoo Khoshakhlagh

Senior Operations Manager

Brett Losen

Co-Founder and Chief Scientific Officer

Alex Ng

Engineering

Hoang Le

Healthcare

Jeremy Velazquez

Senior Scientist II, Team Lead - Functional Biology

Katie Cabral

Principal Research Associate

Muhan Li

Greater Boston Area Companies (Top 10K)

Northeastern US Early Stage Companies With Fewer Than 1000 Employees

Greater Boston Area Therapeutics Female Founded Companies

Therapeutics Early Stage Companies With More Than 10 Employees

GC Therapeutics uses synthetic biology to program patient-derived stem cells into various cell types in an efficient and scalable manner. They have verified cells for several applications by dictating cell fates in a single step. They've also created SuperCells™ by customizing cells for certain conditions. Professor George Church's lab at Harvard Medical School is where GC Therapeutics' fundamental technology was developed, invented, and refined. They are a group of dedicated biologists and tissue engineers whose mission is to bring this ground-breaking method to patients.

Alumni Ventures

Cormorant Asset Management

Series A - GC Therapeutics

Seed Round - GC Therapeutics

Boston

Massachusetts

United States

North America

GC Therapeutics Snares $65 Million Series A

GC Therapeutics Raises $65M in Series A Funding

The Week’s 10 Biggest Funding Rounds: Greentech And Biotech See $200M Raises

Tailored cells designed for specific diseases, created using synthetic biology to program stem cells into any cell type.

A platform that enables the rapid and efficient engineering of a broad spectrum of tissue-specific cell types.

Pakistan

Asia

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Sep 25, 2024 10:03 AM	80910d61
public peers	general	Sep 24, 2024 8:43 AM	58594138
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 24, 2024 11:41 AM	a8aa6940
company summary	general
signals	general	Sep 24, 2024 8:43 AM	e7407c5c
crunchbase trigger	general	Nov 25, 2024 9:06 AM	0c8f296d
crunchbase profile	general	Nov 25, 2024 11:21 AM	38bef429
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:27 PM	8e67253a
peers	general	Sep 24, 2024 8:43 AM	5bad6ac1
news basic	general	Sep 24, 2024 8:43 AM	95ac50c1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GC-TX

GC Therapeutics